ArticleJournal of controlled release : official journal of the Controlled Release Society2009
Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2022Review
- Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy.Molecules (Basel, Switzerland) · 2020Review
- Dual Functionalized 5-Fluorouracil Liposomes as Highly Efficient Nanomedicine for Glioblastoma Treatment as Assessed in an In Vitro Brain Tumor Model.Journal of pharmaceutical sciences · 2018Article
- Mathematical modeling of mutant transferrin-CRM107 molecular conjugates for cancer therapy.Journal of theoretical biology · 2017Article
- Identification of reduction-susceptible disulfide bonds in transferrin by differential alkylation using O(16)/O(18) labeled iodoacetic acid.Journal of the American Society for Mass Spectrometry · 2015Article
- Engineering an Anti-Transferrin Receptor ScFv for pH-Sensitive Binding Leads to Increased Intracellular Accumulation.PloS one · 2015Article
- A new liquid chromatography-mass spectrometry-based method to quantitate exogenous recombinant transferrin in cerebrospinal fluid: a potential approach for pharmacokinetic studies of transferrin-based therapeutics in the central nervous systems.European journal of mass spectrometry (Chichester, England) · 2015Article
- OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma.Molecular cancer · 2014Article
- Enhancing the quality of H/D exchange measurements with mass spectrometry detection in disulfide-rich proteins using electron capture dissociation.Analytical chemistry · 2014Article
- Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.The Journal of membrane biology · 2014Review
- Human serum transferrin: is there a link among autism, high oxalate levels, and iron deficiency anemia?Biochemistry · 2013Article
- Current trends in the use of liposomes for tumor targeting.Nanomedicine (London, England) · 2013Review
- Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin.Advanced drug delivery reviews · 2013Review
- Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.Molecular pharmaceutics · 2013Article
- Biochemical and structural characterization of recombinant human serum transferrin from rice (Oryza sativa L.).Journal of inorganic biochemistry · 2012Article
- The transferrin receptor and the targeted delivery of therapeutic agents against cancer.Biochimica et biophysica acta · 2012Review
- The intracellular trafficking pathway of transferrin.Biochimica et biophysica acta · 2012Review
- Preparation and investigation of bioactive transferrin-iron complexes formed with different synergistic anions.The protein journal · 2012Article
- Toxin-based targeted therapy for malignant brain tumors.Clinical & developmental immunology · 2012Review
- Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Anti-cancer agents in medicinal chemistry · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
We previously demonstrated that decreasing the iron release rate of transferrin (Tf), by replacing the synergistic anion carbonate with oxalate, increases its in vitro drug carrier efficacy in HeLa cells. In the current work, the utility of this strategy has been further explored by generating two Tf mutants, K206E/R632A Tf and K206E/K534A Tf, exhibiting different degrees of iron release inhibition. The intracellular trafficking behavior of these Tf mutants has been assessed by measuring their association with HeLa cells. Compared to native Tf, the cellular association of K206E/R632A Tf and K206E/K534A Tf increased by 126 and 250%, respectively. Surface plasmon resonance studies clearly indicate that this increase in cellular association is due to a decrease in the iron release rate and not to differences in binding affinity of the mutants to the Tf receptor (TfR). Diphtheria toxin (DT) conjugates of K206E/R632A Tf and K206E/K534A Tf showed significantly increased cytotoxicity against HeLa cells with IC(50) values of 1.00 pM and 0.93 pM, respectively, compared to a value of 1.73 pM for the native Tf conjugate. Besides further validating our strategy of inhibiting iron release, these Tf mutants provide proof-of-principle that site-directed mutagenesis offers an alternative method for improving the drug carrier efficacy of Tf.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.